VG801 receives regenerative medicine advanced therapy designation for Stargardt disease
By: Alex Young Fact checked by : Christine Klimanskis, ELS Key takeaways: VG801 is a dual-AAV gene therapy in development for the treatment of Stargardt disease. The therapy is under investigation…